LEXX · XBRL financial data

Lexaria Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LEXX's year ends in late August)

In thousands of dollars	Q4 FY23Aug 31, 2023	Q1 FY23Nov 30, 2023	Q2 FY24Feb 29, 2024	Q3 FY24May 31, 2024	Q4 FY24Aug 31, 2024	Q1 FY25Nov 30, 2024	Q2 FY25Feb 28, 2025	Q3 FY25May 31, 2025	Q4 FY25Aug 31, 2025	Q1 FY26Nov 30, 2025	Q2 FY26Feb 28, 2026	Q3 FY26May 31, 2026
Revenue	(3)*	151	145	84	84*	184	174	174	174*	0	20	0
Revenue from contracts with customers	(3)*	151	145*	84*	84*	184	—	—	—	—	—	—
Cost of goods and services sold	0*	5	0	0	0*	3	0	0	0*	0	0	0
Gross profit	(3)*	146	145	84	84*	181	174	174	174*	0	20	0
Research and development	500*	574	246	573	967*	1,953	1,686	2,718	1,882*	671	475	971
General and administrative	567*	711	567	1,254	1,320*	919	1,239	1,207	980*	902	997	1,023
Total operating expenses	1,067*	1,286	813	1,827	2,287*	2,872	2,925	3,924	2,863*	1,574	1,472	1,994
Operating income (loss)	(1,114)*	(1,139)	(668)	(1,743)	(2,203)*	(2,691)	(2,751)	(3,750)	(2,689)*	(1,574)	(1,452)	(1,994)
Other income (expense)	(135)*	(46)	15	(41)	16*	(16)	—	—	—	—	—	—
Income tax expense (benefit)	—	—	—	—	—	0	0	0	—	2	3	0
Net income (loss)	(1,239)*	(1,179)	(650)	(1,782)	(2,185)*	(2,704)	(2,713)	(3,789)	(2,696)*	(1,595)	(1,450)	(1,991)
Earnings per share, diluted USD per share	—	(0.13)	(0.06)	(0.13)	—	(0.16)	(0.15)	(0.21)	(0.14)*	(0.07)	(0.06)	(0.08)
Weighted average shares, diluted thousands of shares	—	9,052	10,765	13,855	—	16,669	17,512	18,298	19,491*	21,376	24,444	24,806

Balance sheet

CSV

Fiscal quarters (LEXX's year ends in late August)

In thousands of dollars	Q4 FY23Aug 31, 2023	Q1 FY23Nov 30, 2023	Q2 FY24Feb 29, 2024	Q3 FY24May 31, 2024	Q4 FY24Aug 31, 2024	Q1 FY25Nov 30, 2024	Q2 FY25Feb 28, 2025	Q3 FY25May 31, 2025	Q4 FY25Aug 31, 2025	Q1 FY26Nov 30, 2025	Q2 FY26Feb 28, 2026	Q3 FY26May 31, 2026
Cash and cash equivalents	1,352	1,954	4,705	8,459	6,500	8,078	6,500	4,600	1,802	4,300	5,100	3,500
Short-term investments	—	—	—	—	—	—	—	—	143	143	141	142
Marketable securities	126	72	88	46	56	40	74	34	22	0	0	0
Marketable securities, non-current	14	—	—	—	14	—	—	—	349	—	—	—
Accounts receivable	175	535	357	208	154	263	331	358	368	88	42	49
Inventory	0	—	—	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	547	—	267	380	1,188	444	850	823	1,133	851	459	399
Total current assets	2,200	2,694	5,417	9,093	7,898	8,826	7,724	5,807	3,468	5,363	5,770	4,065
Property and equipment, net	254	234	226	219	255	271	262	240	228	216	243	229
Right-of-use asset	167	—	150	143	167	—	157	157	135	—	—	84
Total assets	3,084	3,627	6,352	10,018	8,868	9,794	8,678	6,741	4,175	6,051	6,487	4,781
Total current liabilities	268	125	82	156	1,099	298	1,822	1,488	1,493	1,457	215	383
Lease liability, non-current	—	—	—	—	109	102	94	87	79	71	62	54
Total liabilities	404	254	204	271	1,209	400	1,917	1,575	1,572	1,527	277	437
Accumulated deficit	(45,763)	(46,943)	(47,592)	(49,374)	(51,559)	(54,262)	(56,976)	(60,765)	(63,461)	(65,056)	(66,506)	(68,497)
Total stockholders' equity	3,044	3,742	6,521	10,123	8,036	9,774	7,145	5,552	2,990	4,913	6,602	4,738
Total liabilities and equity	3,084	3,627	6,352	10,018	8,868	9,794	8,678	6,741	4,175	6,051	6,487	4,781
Common shares outstanding (cover page) thousands of shares	10,277	10,435	12,886	15,810	17,453	17,553	17,559	19,559	22,226	24,887	24,787	24,787

Cash flows

CSV

Fiscal quarters (LEXX's year ends in late August)

In thousands of dollars	Q4 FY23Aug 31, 2023	Q1 FY23Nov 30, 2023	Q2 FY24Feb 29, 2024	Q3 FY24May 31, 2024	Q4 FY24Aug 31, 2024	Q1 FY25Nov 30, 2024	Q2 FY25Feb 28, 2025	Q3 FY25May 31, 2025	Q4 FY25Aug 31, 2025	Q1 FY26Nov 30, 2025	Q2 FY26Feb 28, 2026	Q3 FY26May 31, 2026
Net income (loss)	(1,239)*	(1,179)	(650)	(1,782)	(2,185)*	(2,704)	(2,713)	(3,789)	(2,696)*	(1,595)	(1,450)	(1,991)
Stock-based compensation	10*	54	0*	342	97*	99	167*	470*	123*	75	75*	93*
Depreciation and amortization	—	—	—	—	year only	9	9*	22*	12*	12	14*	14*
Net cash from operating activities	(1,622)*	(1,182)	(620)*	(1,266)*	(1,892)*	(2,726)	(1,498)*	(3,584)*	(2,642)*	(984)	(2,164)*	(1,635)*
Purchases of property and equipment	0*	0	0*	0*	43*	25	0*	(0)*	0*	0	41*	0*
Net cash from investing activities	(68)*	(40)	(57)*	(22)*	(70)*	(38)	(28)*	(19)*	(158)*	(5)	(54)*	(27)*
Proceeds from issuing common stock	—	572	492*	3,145*	0*	4,345	12*	1,689*	0*	3,474	3,044*	0*
Proceeds from issuing equity	(122)*	1,248	2,961*	0*	—	—	—	—	—	—	—	—
Net cash from financing activities	(122)*	1,819	3,453*	5,043*	0*	4,345	12*	1,689*	0*	3,474	3,044*	0*
Net change in cash	(1,812)*	602	2,751*	3,754*	(1,959)*	1,578	(1,609)*	(1,877)*	(2,790)*	2,479	847*	(1,653)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lexaria Bioscience	3,500	0	(1,635)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Kala Bio	229	not reported	(1,535)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Curis	5,073	0	(9,646)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Dyadic International	1,425	961	(1,818)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Pulmatrix	2,168	not reported	(1,106)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.